[go: up one dir, main page]

LU92710I2 - Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) - Google Patents

Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) Download PDF

Info

Publication number
LU92710I2
LU92710I2 LU92710C LU92710C LU92710I2 LU 92710 I2 LU92710 I2 LU 92710I2 LU 92710 C LU92710 C LU 92710C LU 92710 C LU92710 C LU 92710C LU 92710 I2 LU92710 I2 LU 92710I2
Authority
LU
Luxembourg
Prior art keywords
antibodies
cyramza
ramucirumab
pharmaceutically acceptable
acceptable derivatives
Prior art date
Application number
LU92710C
Other languages
English (en)
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27805075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92710(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of LU92710I2 publication Critical patent/LU92710I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
LU92710C 2002-03-04 2015-05-06 Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) LU92710I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36178302P 2002-03-04 2002-03-04

Publications (1)

Publication Number Publication Date
LU92710I2 true LU92710I2 (fr) 2015-11-02

Family

ID=27805075

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92710C LU92710I2 (fr) 2002-03-04 2015-05-06 Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)

Country Status (18)

Country Link
US (2) US7498414B2 (fr)
EP (3) EP2298346A3 (fr)
JP (3) JP2005526506A (fr)
AT (2) ATE510561T1 (fr)
AU (1) AU2003213687A1 (fr)
BE (1) BE2015C027I2 (fr)
CA (1) CA2478169C (fr)
CY (3) CY1111141T1 (fr)
DE (1) DE60333554D1 (fr)
DK (2) DK1916001T3 (fr)
ES (2) ES2362931T3 (fr)
FR (1) FR15C0034I2 (fr)
HK (1) HK1118229A1 (fr)
HU (1) HUS1500025I1 (fr)
LU (1) LU92710I2 (fr)
PT (2) PT1916001E (fr)
SI (2) SI1487856T1 (fr)
WO (1) WO2003075840A2 (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510561T1 (de) * 2002-03-04 2011-06-15 Imclone Llc Kdr-spezifische menschliche antikörper und ihre verwendung
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
CN1889979B (zh) * 2003-12-10 2012-09-19 米德列斯公司 Ip-10抗体及其用途
NZ580828A (en) * 2004-02-06 2011-09-30 Univ Massachusetts Antibodies against clostridium difficile toxin B and uses thereof
EP1735348B1 (fr) 2004-03-19 2012-06-20 Imclone LLC Humain anticorps dirige contre le recepteur du facteur de croissance epidermique
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
ES2320374T3 (es) 2005-01-05 2009-05-21 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Dominios de inmunoglobulina sintetica con propiedades de enlace modificadas en regiones de la molecula diferentes de las regiones de determinacion de complementariedad.
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
SI2100618T1 (sl) 2005-06-17 2014-03-31 Imclone Llc Antagonisti receptorja za zdravljenje metastaznega kostnega raka
CN101578376A (zh) * 2005-07-13 2009-11-11 貝丝以色列女执事医疗中心 诊断和治疗炎性应答的方法
ES2411505T3 (es) * 2005-12-15 2013-07-05 Medimmune Limited Combinación del antagonista de la angiopoyetina-2 y del antagonista de VEGF-A, y/o KDR, y/o Flt1 para el tratamiento del cáncer
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP3156415A1 (fr) 2006-11-22 2017-04-19 Bristol-Myers Squibb Company Agents thérapeutiques ciblés sur la base des protéines modifiées de récepteurs de tyrosine kinases, dont le igf-ir
WO2008142165A1 (fr) * 2007-05-24 2008-11-27 Ablynx N.V. Séquences d'acides aminés dirigées contre les récepteurs des facteurs de croissance et polypeptides renfermant ces dernières, destinés au traitement de maladies et affections associées aux facteurs de croissance et à leurs récepteurs
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
EP2158220B1 (fr) 2007-06-26 2017-04-19 F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H Présentation d'agents de liaison
WO2009004066A2 (fr) * 2007-07-03 2009-01-08 Ablynx N.V. Méthodes d'obtention de séquences d'immunoglobuline améliorées
AU2008278803A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to KDR and uses thereof - 035
CL2008003449A1 (es) 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
US8524244B2 (en) 2008-02-14 2013-09-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
EP2113255A1 (fr) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Immunoglobuline cytotoxique
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2011005377A2 (fr) * 2009-05-27 2011-01-13 Mount Sinai School Of Medicine Of New York University Compositions et méthodes utilisant des antagonistes de vegfr-3 destinés à traiter une maladies à métastases
EP2483301A1 (fr) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Récepteurs d'antigènes chimériques anti-récepteur 2 du facteur de croissance de l'endothélium vasculaire, et leur utilisation pour le traitement du cancer
IN2012DN05014A (fr) * 2009-12-29 2015-10-02 Univ Yale
US9328162B2 (en) 2010-02-25 2016-05-03 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (fr) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Administration et formulation d'acides nucleiques genetiquement modifies
CN103619881B (zh) 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
BR112013030352B1 (pt) 2011-06-02 2020-05-19 Dyax Corp anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
AU2012300279A1 (en) 2011-08-26 2014-04-03 Merrimack Pharmaceuticals, Inc. Tandem Fc bispecific antibodies
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112014007852B1 (pt) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc Polinucleotídeo isolado modificado e composição farmacêutica
WO2013067098A1 (fr) 2011-11-02 2013-05-10 Apexigen, Inc. Anticorps anti-kdr et procédés d'utilisation
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151672A2 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de protéines et de peptides associés à l'oncologie
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CN109160950B (zh) * 2012-10-05 2022-10-04 卡德门企业有限公司 人抗vegfr-2/kdr抗体
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
ES2774964T3 (es) 2013-02-04 2020-07-23 Vascular Biogenics Ltd Métodos para inducir la capacidad de respuesta a un agente antiangiogénico
AU2014218318B2 (en) 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
US9618523B2 (en) * 2013-02-28 2017-04-11 Siemens Healthcare Diagnostics Inc. Methods and reagents for determining isomeric analytes
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
TWI558399B (zh) * 2014-02-26 2016-11-21 美國禮來大藥廠 癌症之組合療法
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CN106714839A (zh) 2014-05-15 2017-05-24 百时美施贵宝公司 使用抗pd‑1抗体和另一种抗癌剂的组合治疗肺癌
TWI569808B (zh) 2014-08-15 2017-02-11 禮來大藥廠 肝細胞腫瘤（ｈｃｃ）之治療
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
WO2016057726A2 (fr) 2014-10-07 2016-04-14 Kadmon Corporation, Llc Anticorps humains anti-vegfr-2/kdr
TW201625304A (zh) 2014-10-24 2016-07-16 美國禮來大藥廠 泌尿上皮癌之療法
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (fr) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Traitement du néphrocarcinome
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
HUE053966T2 (hu) 2015-07-14 2021-08-30 Bristol Myers Squibb Co Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1)
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
TW201736399A (zh) * 2015-12-31 2017-10-16 財團法人生物技術開發中心 抗vegfr抗體及其應用
US20190125864A1 (en) 2016-04-15 2019-05-02 Eli Lilly And Company Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma
US20190336599A1 (en) * 2016-04-15 2019-11-07 Eli Lilly And Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
LT3458053T (lt) 2016-05-20 2022-02-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
WO2017210119A1 (fr) 2016-06-03 2017-12-07 Imclone Llc Combinaison de ramucirumab et de pembrolizumab pour le traitement de certains cancers
WO2018069871A2 (fr) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Protéines de liaison anti-kras
JP2019534888A (ja) 2016-10-28 2019-12-05 イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ 癌の治療のための抗ｖｅｇｆｒ−２抗体と抗ｐｄ−ｌ１抗体との組み合わせ
WO2018098363A2 (fr) * 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation
CN106674349B (zh) * 2017-03-07 2018-03-13 北京东方百泰生物科技有限公司 一种改进的抗vegfr‑2单克隆抗体
KR20200013644A (ko) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종의 치료
EP3672633A1 (fr) 2017-08-21 2020-07-01 Eli Lilly and Company Combinaisons d'inhibiteurs d'egfr et d'anticorps anti-vegfr -2 humains
JP2021500355A (ja) 2017-10-20 2021-01-07 バスキュラー バイオジェニックス リミテッド 抗血管新生薬剤療法のための診断方法
WO2020006509A1 (fr) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antagonistes antitumoraux
MX2021005808A (es) 2018-11-20 2021-07-02 Univ Cornell Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
WO2020183424A1 (fr) 2019-03-13 2020-09-17 Vascular Biogenics Ltd. Procédés de thérapie antitumorale
CN114340735B (zh) 2019-06-28 2024-11-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
WO2021020979A1 (fr) 2019-07-31 2021-02-04 Memorial Sloan Kettering Cancer Center Sculpture de dose de tumeur modulée par perfusion avec radiothérapie à dose unique
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
CN111024949A (zh) * 2019-12-31 2020-04-17 上海博威生物医药有限公司 一种重组抗vegfr2单克隆抗体的生物活性分析方法及其应用
CA3189987A1 (fr) 2020-09-02 2022-03-10 Pharmabcine Inc. Polytherapie d'un antagoniste de pd-1 et d'un antagoniste de vegfr-2 pour traiter des patients cancereux
CN114316064B (zh) * 2020-10-10 2024-07-26 广东菲鹏制药股份有限公司 融合蛋白及其应用
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022256820A1 (fr) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Antagonistes multispécifiques
JP2025501238A (ja) 2021-12-30 2025-01-17 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とｖｅｇｆアンタゴニストの併用による腫瘍の治療方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328695A (en) 1983-03-22 1994-07-12 Massachusetts Institute Of Technology Muscle morphogenic protein and use thereof
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4683295A (en) 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE4103975A1 (de) 1991-02-09 1992-08-13 Thomson Brandt Gmbh Verfahren zur verkuerzung der zugriffszeit
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
US20010021382A1 (en) 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5672499A (en) 1992-07-27 1997-09-30 California Institute Of Technology Immoralized neural crest stem cells and methods of making
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
WO1994013804A1 (fr) 1992-12-04 1994-06-23 Medical Research Council Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
JP3670302B2 (ja) 1993-07-23 2005-07-13 ファナック株式会社 射出成形機における可塑化の管理方法
US5599703A (en) 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
AT402796B (de) 1995-02-01 1997-08-25 Fritschi Apparatebau Schibindung
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
JP3658471B2 (ja) 1996-09-30 2005-06-08 株式会社日立製作所 電子ショッピングシステムにおける買物かご機能の提示方法及び電子ショッピングシステム
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
DE69736222T2 (de) 1996-11-21 2007-05-24 Kyowa Hakko Kogyo K.K. Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
ES2292204T3 (es) 1997-06-18 2008-03-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Receptor de tipo tirosina cinasa humano, kdr.
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
CZ20004224A3 (cs) 1998-05-15 2002-02-13 Imclone Systems Incorporated Neradioaktivně značený inhibitor proteinového tyrosinkinázového receptoru
US20020172678A1 (en) * 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE60032459D1 (de) 1999-01-15 2007-02-01 Medstar Res Inst Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1
JP2002536968A (ja) 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
CZ20023518A3 (cs) 2000-03-31 2004-04-14 Imclone Systems Incorporated Léčivo pro inhibici růstu buněk non-solidních nádorů
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2003000183A2 (fr) 2001-06-20 2003-01-03 Imclone Systems Incorporated Procedes de traitement de l'atherosclerose et d'autres maladies inflammatoires
US20040242851A1 (en) 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
US6519852B1 (en) 2001-07-26 2003-02-18 Yuecom Manufacturing Co., Ltd. Method of manufacturing an aluminum alloy wheel rim
ATE510561T1 (de) * 2002-03-04 2011-06-15 Imclone Llc Kdr-spezifische menschliche antikörper und ihre verwendung
US6844779B2 (en) 2003-06-19 2005-01-18 The United States Of America As Represented By The Secretary Of The Air Force Optically isolated bias control circuit

Also Published As

Publication number Publication date
US7498414B2 (en) 2009-03-03
PT1487856E (pt) 2010-09-29
EP1916001A3 (fr) 2008-08-13
US8057791B2 (en) 2011-11-15
AU2003213687A1 (en) 2003-09-22
EP1916001A2 (fr) 2008-04-30
JP2005526506A (ja) 2005-09-08
WO2003075840A2 (fr) 2003-09-18
CY1111629T1 (el) 2015-10-07
WO2003075840A3 (fr) 2004-04-29
HUS1500025I1 (hu) 2017-04-28
SI1487856T1 (sl) 2010-12-31
DK1487856T3 (da) 2010-10-18
BE2015C027I2 (fr) 2022-05-19
DK1916001T3 (da) 2011-07-18
CY1111141T1 (el) 2015-06-11
ATE510561T1 (de) 2011-06-15
EP1487856B1 (fr) 2010-07-28
ES2347543T3 (es) 2010-11-02
FR15C0034I2 (fr) 2016-08-26
EP2298346A2 (fr) 2011-03-23
CA2478169C (fr) 2013-04-16
PT1916001E (pt) 2011-07-18
EP1487856A4 (fr) 2006-08-23
ES2362931T3 (es) 2011-07-15
US20090142358A1 (en) 2009-06-04
AU2003213687A8 (en) 2003-09-22
ATE475431T1 (de) 2010-08-15
DE60333554D1 (de) 2010-09-09
CA2478169A1 (fr) 2003-09-18
SI1916001T1 (sl) 2011-10-28
FR15C0034I1 (fr) 2015-06-26
EP2298346A3 (fr) 2011-11-16
CY2015018I1 (el) 2016-04-13
JP2009148298A (ja) 2009-07-09
EP1487856A2 (fr) 2004-12-22
JP4970483B2 (ja) 2012-07-04
HK1118229A1 (en) 2009-02-06
US20050234225A1 (en) 2005-10-20
CY2015018I2 (el) 2016-04-13
JP2012105667A (ja) 2012-06-07
EP1916001B1 (fr) 2011-05-25
JP5476404B2 (ja) 2014-04-23

Similar Documents

Publication Publication Date Title
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
CY1121796T1 (el) Συνθεσεις μονοσθενεις για δεσμευση cd28 και μεθοδοι χρησης
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
CY1117617T1 (el) Αντισωματα ige εναντι ανθρωπου υψηλης συναφειας
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
CY1116167T1 (el) Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1113037T1 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
ATE465181T1 (de) Humanisierte anti-cmet-antagonisten
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
DE602006013029D1 (de) Anti-egfr-antikörper
CY1117275T1 (el) Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους
CY1115979T1 (el) Αντισωματα κατα της μυοστατινης